Ventyx Biosciences/$VTYX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Ticker
$VTYX
Sector
Primary listing
Employees
81
Headquarters
Website
VTYX Metrics
BasicAdvanced
$587M
-
-$1.68
0.97
-
Price and volume
Market cap
$587M
Beta
0.97
52-week high
$9.50
52-week low
$0.78
Average daily volume
7.1M
Financial strength
Current ratio
19.123
Quick ratio
18.307
Long term debt to equity
4.373
Total debt to equity
4.917
Profitability
EBITDA (TTM)
-130.108
Management effectiveness
Return on assets (TTM)
-30.23%
Return on equity (TTM)
-48.56%
Valuation
Price to book
2.8
Price to tangible book (TTM)
2.8
Price to free cash flow (TTM)
-5.522
Free cash flow yield (TTM)
-18.11%
Free cash flow per share (TTM)
-1.49
Growth
Earnings per share change (TTM)
-38.72%
3-year earnings per share growth (CAGR)
-5.71%
What the Analysts think about VTYX
Analyst ratings (Buy, Hold, Sell) for Ventyx Biosciences stock.
Bulls say / Bears say
A $27 million strategic investment by Sanofi in September 2024 validated VTX3232’s potential, extended Ventyx’s cash runway at least into H2 2026, and gave Sanofi exclusive first-negotiation rights on the CNS-penetrant NLRP3 program (Nasdaq)
Data presented at ECCO 2025 showed VTX958 achieved statistically significant reductions in endoscopic SES-CD scores compared to placebo (–3.5 and –2.7 points for 225 mg and 300 mg BID, respectively; p < 0.0005), clearly demonstrating mucosal healing in Crohn’s disease (Journal of Crohn’s and Colitis via Ventyx IR release)
Ventyx ended Q2 2025 with $209.0 million in cash, cash equivalents, and marketable securities—providing funding through H2 2026 to support several upcoming Phase 2 readouts in its NLRP3, TYK2, and S1P1R programs (Ventyx IR release)
VTX958 failed to meet the primary endpoint in its Phase 2 Crohn’s disease trial, with CDAI reductions of –134.1 (225 mg) and –113.6 (300 mg) compared to –104.3 for placebo (p > 0.05), casting doubt on its efficacy in IBD indications (Journal of Crohn’s and Colitis via Ventyx IR release)
Ventyx reported a net loss of $27.0 million in Q2 2025, highlighting ongoing high operating costs and continued pressure on liquidity, despite improving from a $32.0 million loss the prior year (Ventyx IR release)
VTYX shares have traded in a wide 52-week range—from $0.78 to $3.39—showing significant price volatility and continued market skepticism about the company’s clinical and commercial outlook (CNBC)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2025.
VTYX Financial Performance
Revenues and expenses
VTYX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ventyx Biosciences stock?
Ventyx Biosciences (VTYX) has a market cap of $587M as of November 04, 2025.
What is the P/E ratio for Ventyx Biosciences stock?
The price to earnings (P/E) ratio for Ventyx Biosciences (VTYX) stock is 0 as of November 04, 2025.
Does Ventyx Biosciences stock pay dividends?
No, Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Ventyx Biosciences dividend payment date?
Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ventyx Biosciences?
Ventyx Biosciences (VTYX) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.